Ying Zan,Xiaoyan Gao,Hongbing Ma,Liang Ling,Yuguang Ma,Wentao Hui. A retrospective clinical study of safety and efficacy of vinorelbine/epirubicin/fluorouracil (NEF) regimen as a postoperative chemotherapy for breast cancer. Oncol Transl Med, 2014, 13: 264-266.
A retrospective clinical study of safety and efficacy of vinorelbine/epirubicin/fluorouracil (NEF) regimen as a postoperative chemotherapy for breast cancer
  
View Full Text  View/Add Comment  Download reader
KeyWord:vinorelbine/epirubicin/fluorouracil; breast cancer; adjuvant chemotherapy
Author NameAffiliation
Ying Zan Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710004, China 
Xiaoyan Gao Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710005, China 
Hongbing Ma Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710006, China 
Liang Ling Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710007, China 
Yuguang Ma Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710008, China 
Wentao Hui Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710009, China 
Hits: 6467
Download times: 6830
Abstract:
      Objective: We aimed to investigate the safety and efficiency of vinorelbine/epirubicin/fluorouracil (NEF) regimen as adjuvant chemotherapy for breast cancer. Methods: From 2005 to 2008, 227 female breast cancer patients were treated with the NEF regimen: vinorelbine 25 mg/m2 iv on days 1 and 8; epirubicin 60 mg/m2 iv gtt on day 1; 5-Fu 500 mg/m2 iv gtt on day 1. Chemotherapy was repeated every 21–28 days for a total of 6 cycles. Results: The major side effects were neutropenia and gastrointestinal syndrome, with a 5-year survival rate of 85.4%. Conclusion: NEF regimen is safe and guarantees a high survival rate which could be recommended as a adjuvant chemotherapy regimen for breast cancer.
Close